Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide in chronic kidney disease stage 4–5 with osteoporosis or osteopenia
jRCTs041240136Recruiting
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of teriparatide in osteoporosis and osteopenia. Primary endpoint: Increase in trabecular bone score in lumbar spine bone mineral density after 2 years. Started Oct 2025; status: recruiting.
02
Drugs
teriparatide
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on jRCTs041240136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240136.